Table 3 Median Visual Acuity and Central Macular Thickness (CMT) Over 12 Months Follow-Up
From: Clinical outcomes of pediatric macular edema associated with non-infectious uveitis
Outcome | Baseline | 3 Months | 6 Months | 9 Months | 12 Months |
|---|---|---|---|---|---|
Median BCVA in logMAR | 0.54 (IQR 0.3–1.0, n = 26) | 0.30 (IQR 0.1–0.5, n = 26) | 0.20 (IQR 0.1–0.6, n = 26) | 0.15 (IQR 0–0.5, n = 24) | 0.1 (IQR 0–0.4, n = 21) |
Median BCVA in Snellen | 20/69, IQR 20/40 to 20/200 | 20/40, IQR 20/25 to 20/69 | 20/32, IQR 20/25 to 20/79 | 20/28, IQR 20/20 to 20/69 | 20/25, IQR 20/20 to 20/50 |
CMT (microns) | 424 (IQR 352–620.5, n = 23) | 325 (IQR 283–347, n = 21) | 310 (IQR 298–325, n = 22) | 305 (IQR 285–319, n = 19) | 302 (IQR 281–340, n = 18) |